CBT-004 is a novel, preservative-free ophthalmic solution targeting VEGF and PDGF receptors to treat vascularized pinguecula. Phase 2 trial results showed significant improvements in conjunctival ...

Please provide your email address to receive an email when new articles are posted on . Second-generation anti-VEGF therapies include aflibercept 8 mg and faricimab. Early intervention can prevent ...

Please provide your email address to receive an email when new articles are posted on . From 2017 to 2022, aflibercept was the most commonly used anti-VEGF agent in all U.S. Census regions.

President and Chief Executive Officer — Jay S. Duker, M.D. Chief Financial Officer — George O. Elston Chief Medical Officer — Ramiro Ribeiro, M.D. Management expects DuraVu to be the only tyrosine ...

This newly published review article offers a comprehensive examination of the complexities of tumor angiogenesis and the origins of endothelial cells (ECs) within tumors. Tumor angiogenesis, a ...

Programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF) are often co-expressed in the tumor microenvironment. The combination of anti-PD-1 and anti-VEGF agents has been ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...

The U.S. radiation oncology market is calculated at USD 6.65 billion in the year 2023, which grew at USD 7.19 billion in the year 2024 and is estimated to reach around USD 14.56 billion in the year ...

Platelet-derived growth factors (PDGFs) are mitogenic during early development, promoting the proliferation of undifferentiated mesenchymal cells and specific progenitor populations. At later ...

Researchers led by a team at the Wilmer Eye Institute, Johns Hopkins Medicine, have discovered why vision in some patients with neovascular (nv) or “wet” age-related macular degeneration (nvAMD, or ...

CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a wide variety of off-label indications and add hundreds of millions of dollars ...